|
1
|
Collison LW, Workman CJ, Kuo TT, Boyd K,
Wang Y, Vignali KM, Cross R, Sehy D, Blumberg RS and Vignali DA:
The inhibitory cytokine IL-35 contributes to regulatory T-cell
function. Nature. 450:566–569. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Niedbala W, Wei XQ, Cai B, Hueber AJ,
Leung BP, McInnes IB and Liew FY: IL-35 is a novel cytokine with
therapeutic effects against collagen-induced arthritis through the
expansion of regulatory T cells and suppression of Th17 cells. Eur
J Immunol. 37:3021–3029. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kochetkova I, Golden S, Holderness K,
Callis G and Pascual DW: IL-35 stimulation of CD39+ regulatory T
cells confers protection against collagen II-induced arthritis via
the production of IL-10. J Immunol. 184:7144–7153. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shao Y, Fu R, Liu H, Wang Y, Ding S, Wang
H, Li L and Shao Z: IgG autoantibody subclasses altered in
immuno-related hemocytopenia. Cell Immunol. 294:13–20. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fu R, Liu H, Wang Y, Liu H, He H, Chen J,
Wang H, Yu H, Ding K, Huang L, et al: Distinguishing immunorelated
haemocytopenia from idiopathic cytopenia of undetermined
significance (ICUS): A bone marrow abnormality mediated by
autoantibodies. Clin Exp Immunol. 177:412–418. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fu R, Shao Z, He H, Liu H, Jia H, Sun J,
Zhao M, He G, Shi J, Bai J, et al: Quantity and apoptosis-related
protein level of B lymphocyte in patients with immunorelated
pancytopenia. Zhonghua Xue Ye Xue Za Zhi. 23:236–238. 2002.(In
Chinese). PubMed/NCBI
|
|
7
|
Fu R, Chen J, Wang HL, Wang J, Li LJ, Liu
H, Wang YH, Ren Y and Shao ZH: Quantity and function of regulatory
T cells in hemocytopenic patients with positive BMMNC-Coombs test.
Zhonghua Yi Xue Za Zhi. 90:2989–2993. 2010.(In Chinese). PubMed/NCBI
|
|
8
|
Fu R, Wang HL, Chen J, Wang J, Li LJ, Liu
H, Wang YH, Ren Y and Shao ZH: Study of the quantity and function
of Th17 cells in the blood cytopenic patients with positive
BMMNC-Coombs test. Zhonghua Xue Ye Xue Za Zhi. 31:684–687. 2010.(In
Chinese). PubMed/NCBI
|
|
9
|
Zhu X, Guan J, Xu J, Wei J, Jiang L, Yin
J, Zhao L and Zhang Y: Pilot study using tacrolimus rather than
cyclosporine plus antithymocyte globulin as an immunosuppressive
therapy regimen option for severe aplastic anemia in adults. Blood
Cells Mol Dis. 53:157–160. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Valent P, Horny HP, Bennett JM, Fonatsch
C, Germing U, Greenberg P, Haferlach T, Haase D, Kolb HJ, Krieger
O, et al: Definitions and standards in the diagnosis and treatment
of the myelodysplastic syndromes: Consensus statements and report
from a working conference. Leuk Res. 31:727–736. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ando K, Kodama A, Iwabuchi T, Ohyashiki JH
and Ohyashiki K: Idiopathic neutropenia with fewer than 5%
dysplasia may be a distinct entity of idiopathic cytopenia of
undetermined significance. Ann Hematol. 89:733–735. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nicoletti F, Zaccone P, Di Marco R,
Lunetta M, Magro G, Grasso S, Meroni P and Garotta G: Prevention of
spontaneous autoimmune diabetes in diabetes-prone BB rats by
prophylactic treatment with antirat interferon-gamma antibody.
Endocrinology. 138:281–288. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nicoletti F, Di Marco R, Zaccone P, Magro
G, Di Mauro M, Grasso S and Meroni PL: Endogenous interleukin-12
only plays a key pathogenetic role in non-obese diabetic mouse
diabetes during the very early stages of the disease. Immunology.
97:367–370. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nicoletti F, Zaccone P, Xiang M, Magro G,
Di Mauro M, Di Marco R, Garotta G and Meroni P: Essential
pathogenetic role for interferon (IFN-)gamma in concanavalin
A-induced T cell-dependent hepatitis: Exacerbation by exogenous
IFN-gamma and prevention by IFN-gamma receptor-immunoglobulin
fusion protein. Cytokine. 12:315–323. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nicoletti F, Di Marco R, Zaccone P,
Salvaggio A, Magro G, Bendtzen K and Meroni P: Murine concanavalin
A-induced hepatitis is prevented by interleukin 12 (IL-12) antibody
and exacerbated by exogenous IL-12 through an
interferon-gamma-dependent mechanism. Hepatology. 32:728–733. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tang H, Mignon-Godefroy K, Meroni PL,
Garotta G, Charreire J and Nicoletti F: The effects of a monoclonal
antibody to interferon-gamma on experimental autoimmune thyroiditis
(EAT): Prevention of disease and decrease of EAT-specific T cells.
Eur J Immunol. 23:275–278. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zaccone P, Hutchings P, Nicoletti F, Penna
G, Adorini L and Cooke A: The involvement of IL-12 in murine
experimentally induced autoimmune thyroid disease. Eur J Immunol.
29:1933–1942. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li R, Zheng X, Popov I, Zhang X, Wang H,
Suzuki M, Necochea-Campion RD, French PW, Chen D, Siu L, et al:
Gene silencing of IL-12 in dendritic cells inhibits autoimmune
arthritis. J Transl Med. 10:192012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Karri SK and Sheela A: Potential route of
Th17/Treg cell dynamics in targeting type 1 diabetes and rheumatoid
arthritis: An autoimmune disorder perspective. Br J Biomed Sci.
74:8–15. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dong Z, Du L, Xu X, Yang Y, Wang H, Qu A,
Qu X and Wang C: Aberrant expression of circulating Th17, Th1 and
Tc1 cells in patients with active and inactive ulcerative colitis.
Int J Mol Med. 31:989–997. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rostami A and Ciric B: Role of Th17 cells
in the pathogenesis of CNS inflammatory demyelination. J Neurol
Sci. 333:76–87. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Deepak P and Loftus EV Jr: Ustekinumab in
treatment of Crohn's disease: Design, development, and potential
place in therapy. Drug Des Devel Ther. 10:3685–3698. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bai F, Tian H, Niu Z, Liu M, Ren G, Yu Y,
Sun T, Li S and Li D: Chimeric anti-IL-17 full-length monoclonal
antibody is a novel potential candidate for the treatment of
rheumatoid arthritis. Int J Mol Med. 33:711–721. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Reszke R and Szepietowski JC: Secukinumab
in the treatment of psoriasis: An update. Immunotherapy. 9:229–238.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vignali DA and Kuchroo VK: IL-12 family
cytokines: Immunological playmakers. Nat Immunol. 13:722–728. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sun L, He C, Nair L, Yeung J and Egwuagu
CE: Interleukin 12 (IL-12) family cytokines: Role in immune
pathogenesis and treatment of CNS autoimmune disease. Cytokine.
75:249–255. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Olson BM, Sullivan JA and Burlingham WJ:
Interleukin 35: A key mediator of suppression and the propagation
of infectious tolerance. Front Immunol. 4:3152013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hou C, Wu Q, Ouyang C and Huang T: Effects
of an intravitreal injection of interleukin-35-expressing plasmid
on pro-inflammatory and anti-inflammatory cytokines. Int J Mol Med.
38:713–720. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Guan SY, Leng RX, Khan MI, Qureshi H, Li
XP, Ye DQ and Pan HF: Interleukin-35: A potential therapeutic agent
for autoimmune diseases. Inflammation. 40:303–310. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Egwuagu CE, Yu CR, Sun L and Wang R:
Interleukin 35: Critical regulator of immunity and
lymphocyte-mediated diseases. Cytokine Growth Factor Rev.
26:587–593. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hori S, Nomura T and Sakaguchi S: Control
of regulatory T cell development by the transcription factor Foxp3.
Science. 299:1057–1061. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang W, Li P, Chen YF and Yang J: A
potential immunopathogenic role for reduced IL-35 expression in
allergic asthma. J Asthma. 52:763–771. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhou Y, Zhang H and Li Y: IL-35 expression
in peripheral blood CD4(+) T cells from chronic hepatitis B
virus-infected patients directly correlates with virus load.
Cytokine. 73:169–175. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shi M, Wei J, Dong J, Meng W, Ma J, Wang
T, Wang N and Wang Y: Function of interleukin-17 and −35 in the
blood of patients with hepatitis B-related liver cirrhosis. Mol Med
Rep. 11:121–126. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang Y, Dong J, Meng W, Ma J, Wang N, Wei
J and Shi M: Effects of phased joint intervention on IL-35 and
IL-17 expression levels in patients with portal hypertension. Int J
Mol Med. 33:1131–1139. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Collison LW, Chaturvedi V, Henderson AL,
Giacomin PR, Guy C, Bankoti J, Finkelstein D, Forbes K, Workman CJ,
Brown SA, et al: IL-35-mediated induction of a potent regulatory T
cell population. Nat Immunol. 11:1093–1101. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wong CK, Leung TF, Chu IM, Dong J, Lam YY
and Lam CW: Aberrant expression of regulatory cytokine IL-35 and
pattern recognition receptor NOD2 in patients with allergic asthma.
Inflammation. 38:348–360. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ghaedi M, Namdari H, Rahimzadeh P, Morteza
Gholi S, Azimi Mohamadabadi M and Salehi E: Different doses of
transforming growth factor-b on in vitro differentiation of human
naive CD4+ T cells to T helper 17. Iran J Allergy Asthma Immunol.
14:633–637. 2015.PubMed/NCBI
|
|
40
|
Ghoreschi K, Laurence A, Yang XP, Tato CM,
McGeachy MJ, Konkel JE, Ramos HL, Wei L, Davidson TS, Bouladoux N,
et al: Generation of pathogenic T(H)17 cells in the absence of
TGF-β signalling. Nature. 467:967–971. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Volpe E, Servant N, Zollinger R, Bogiatzi
SI, Hupé P, Barillot E and Soumelis V: A critical function for
transforming growth factor-beta, interleukin 23 and proinflammatory
cytokines in driving and modulating human T(H)-17 responses. Nat
Immunol. 9:650–657. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chung Y, Yamazaki T, Kim BS, Zhang Y,
Reynolds JM, Martinez GJ, Chang SH, Lim H, Birkenbach M and Dong C:
Epstein Barr virus-induced 3 (EBI3) together with IL-12 negatively
regulates T helper 17-mediated immunity to Listeria monocytogenes
infection. PLoS Pathog. 9:e10036282013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Presky DH, Yang H, Minetti LJ, Chua AO,
Nabavi N, Wu CY, Gately MK and Gubler U: A functional interleukin
12 receptor complex is composed of two beta-type cytokine receptor
subunits. Proc Natl Acad Sci USA. 93:pp. 14002–14007. 1996;
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Collison LW, Delgoffe GM, Guy CS, Vignali
KM, Chaturvedi V, Fairweather D, Satoskar AR, Garcia KC, Hunter CA,
Drake CG, et al: The composition and signaling of the IL-35
receptor are unconventional. Nat Immunol. 13:290–299. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Behzadi P, Behzadi E and Ranjbar R: IL-12
family cytokines: General characteristics, pathogenic
microorganisms, receptors, and signalling pathways. Acta Microbiol
Immunol Hung. 63:1–25. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Liu H and Rohowsky-Kochan C:
Interleukin-27-mediated suppression of human Th17 cells is
associated with activation of STAT1 and suppressor of cytokine
signaling protein 1. J Interferon Cytokine Res. 31:459–469. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Peters A, Fowler KD, Chalmin F, Merkler D,
Kuchroo VK and Pot C: IL-27 induces Th17 differentiation in the
absence of STAT1 signaling. J Immunol. 195:4144–4153. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Cai Z, Wong CK, Dong J, Chu M, Jiao D, Kam
NW, Lam CW and Tam LS: Remission of systemic lupus erythematosus
disease activity with regulatory cytokine interleukin (IL)-35 in
Murphy Roths Large (MRL)/lpr mice. Clin Exp Immunol. 181:253–266.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Li Y, Wu S, Li Y, Jiang S, Lin T, Xia L,
Shen H and Lu J: Interleukin-35 (IL-35) inhibits proliferation and
promotes apoptosis of fibroblast-like synoviocytes isolated from
mice with collagen-induced arthritis. Mol Biol Rep. 43:947–956.
2016. View Article : Google Scholar : PubMed/NCBI
|
